


FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
KC	*	US2002/0130430	12/29/00	Castor			09/12/02
	*	US2002/0137210		Churikov			09/26/02
	*	10/201,394	08/13/01	Vargeese et al.			
	*	60/082,404	04/20/98	Thompson et al.			
	*	60/358,580	02/20/02	Beigelman et al.			
	*	60/362,016	03/06/02	Matulic-Adamic et al.			
	*	60/363,124	03/11/02	Beigelman et al.			
	*	60/402,996	08/13/02	Usman et al.			
	*	60/406,784	08/29/02	Beigelman et al.			
	*	60/408,378	09/05/02	Beigelman et al.			
	*	60/409,293	09/09/02	Beigelman et al.			
	*	60/440,129	01/15/03	Beigelman et al.			

EXAMINER

DATE CONSIDERED

12/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
ke	*	5,334,711	08/02/94	Sproat			
	*	5,624,803	04/29/97	Noonberg et al.			
	*	5,627,053	05/06/97	Usman et al.			
	*	5,631,360	05/20/97	Usman et al.			
	*	5,672,695	09/30/97	Eckstein et al.			
	*	5,716,824	02/10/98	Beigelman et al.			
	*	5,804,683	09/08/98	Usman et al.			
	*	5,831,071	11/03/98	Usman et al.			
	*	5,854,038	12/29/98	Cech et al.			
	*	5,889,136	03/30/99	Scaringe et al.			
	*	5,902,880	05/11/99	Thompson et al.			
	*	5,998,203	12/07/99	Adamic et al.			
	*	6,001,311	12/14/99	Brennan			
	*	6,008,400	12/28/99	Scaringe et al.			
	*	6,054,576	04/25/00	Bellon et al.			

EXAMINER

DATE CONSIDERED

12/15/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-332-B (400/126)	Serial No. 10/652,791
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: August 29, 2003	Group:

KC	*	6,111,086	08/29/00	Scaringe et al.			
	*	6,117,657	09/12/00	Usman et al.			
	*	6,146,886	11/14/00	Thompson et al.			
	*	6,162,909	12/19/00	Bellon et al.			
	*	6,248,878	06/19/01	Adamic et al.			
	*	6,300,074	10/09/01	Gold			
	*	6,303,773	10/16/01	Bellon et al.			
	*	6,353,098	03/05/02	Usman et al.			
	*	6,362,323	03/26/01	Usman et al.			
	*	6,395,713	05/28/02	Beigelman et al.			
	*	6,437,117	08/20/02	Usman et al.			
	*	6,447,796	09/10/02	Vook et al.			
	*	6,469,158	10/22/02	Usman et al.			
✓	*	6,506,559	06/14/03	Fire et al.			

EXAMINER	DATE CONSIDERED
	12/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
K								
KC	1. ✓	2,359,180	08/03/00	CA (Kreutzer et al.)				
	2. ✓	1144623 B1	01/29/02	EP (Kreutzer et al.)				
	3. ✓	89/02439	03/23/89	WO (Arnold et al.)				
	4. ✓	91/03162	03/21/91	WO (Rossi et al.)				
	5. ✓	92/07065	04/30/92	WO (Eckstein et al.)				
	6. ✓	93/15187	08/05/93	WO (Usman et al.)				
	7. ✓	93/23569	11/25/93	WO (Draper et al.)				
	8. ✓	94/02595	02/03/94	WO (Sullivan et al.)				
	9. ✓	95/06731	03/09/95	WO (Usman et al.)				
	10. ✓	95/11910	05/04/95	WO (Dudycz et al.)				
	11. ✓	96/10390	04/11/96	WO (Ansell et al.)				
	12. ✓	96/10391	04/11/96	WO (Choi et al.)				
	13. ✓	96/10392	04/11/96	WO (Holland et al.)				
✓	14. ✓	97/26270	07/24/97	WO (Beigelman et al.)				

EXAMINER

DATE CONSIDERED

12/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:

KC	15	98/13526	04/02/98	WO (Woolf et al.)				
	16	99/07409	02/18/99	WO (Deschamps de Paillette et al.)				
	17	99/14226	03/25/99	WO (Wengel et al.)				
	18	99/31262	06/24/99	WO (Barry et al.)				
	19	99/32619	07/01/99	WO (Fire et al.)				
	20	99/49029	09/30/99	WO (Graham et al.)				
	21	99/53050	10/21/99	WO (Waterhouse et al.)				
	22	99/54459	10/28/99	WO (Thompson et al.)				
	23	00/01846	01/13/00	WO (Plaetinck et al.)				
	24	00/44895	08/03/00	WO (Kreutzer et al.)				
	25	00/44914	08/03/00	WO (Li et al.)				
	26	00/53722	09/14/00	WO (O'Hare and Normand)				
	27	00/63364	10/26/00	WO (Pachuk et al.)				
	28	00/66604	11/09/00	WO (Wengel et al.)				
	29	01/04313	01/18/01	WO (Satishchandran et al.)				
	30	01/29058	04/26/01	WO (Mello et al.)				
✓	31	01/36646	05/25/01	WO (Zernicka-Goetz et al.)				

EXAMINER

DATE CONSIDERED

12/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:

KC	32	01/38551	05/31/01	WO (Grossniklaus)				
	33	01/42443	06/14/01	WO (Churikov et al.)				
	34	01/49844	07/12/01	WO (Driscoll et al.)				
	35	01/53475	07/26/01	WO (Cogoni et al.)				
	36	01/68836	09/20/01	WO (Beach et al.)				
	37	01/70944	09/27/01	WO (Honer et al.)				
	38	01/70949	09/27/01	WO (Graham et al.)				
	39	01/72774	10/04/01	WO (Deak et al.)				
	40	01/75164	10/11/01	WO (Tuschl et al.)				
	41	01/92513	05/29/01	WO (Arndt et al.)				
	42	02/38805	05/16/02	WO (Echeverri et al.)				
	43	02/44321	06/06/02	WO (Tuschl et al.)				
	44	02/55692	07/18/02	WO (Kreutzer et al.)				
	45	02/55693	07/18/02	WO (Kreutzer et al.)				
	46	03/05028	02/20/03	WO (McSwiggen et al.)				
	47	03/05346	02/20/03	WO (McSwiggen et al.)				

EXAMINER

[Signature]

DATE CONSIDERED


12/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-332-B (400/126)	Serial No. 10/652,791
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: August 29, 2003	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

KC	48. ✓ Akhtar and Juliano, "Cellular Uptake and Intracellular Fate of AntiSense-Oligonucleotides," <u>Trends Cell Biol.</u> 2:139-144 (1992)
	49. ✓ Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a <i>retro-inverso</i> delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <u>Nucleic Acids Research</u> 26:4910-4916 (1998)
	50. ✓ Allshire, "RNAi and Heterochromatin - A Hushed-up Affair," <u>Science</u> 297:1818-1819 (2002)
	51. ✓ Andrews and Faller, "A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells," <u>Nucleic Acids Research</u> 19:2499 (1991)
	52. ✓ Baenziger and Fiete, "Galactose and N-Acetylgalactosamine-Specific Endocytosis of Glycopeptides by Isolated Rat Hepatocytes," <u>Cell</u> 22:611-620 (1980)
	53. ✓ Bass, "The short answer," <u>Nature</u> 411:428-429 (2001)
	54. ✓ Beaucage and Iyer, "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," <u>Tetrahedron</u> 49:1925-1963 (1993)
	55. ✓ Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <u>The Journal of Biological Chemistry</u> 270:25702-25708 (1995)
	56. ✓ Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <u>Nucleosides & Nucleotides</u> 16:951-954 (1997)
↓	57. ✓ Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis," <u>Bioconjugate Chem.</u> 8:204-212 (1997)

EXAMINER 	DATE CONSIDERED 12/5/05
--	-------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:

KC	58.	Berkman et al., "Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms," <i>The Journal of Clinical Investigation, Inc.</i> 91:153-159 (1993)
	59.	Bernstein et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference," <i>Nature</i> 409:363-366 (2001)
	60.	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)
	61.	Boado, "Antisense drug delivery through the blood-brain barrier," <i>Advanced Drug Delivery Reviews</i> 15:73-107 (1995)
	62.	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," <i>Biotechnology and Bioengineering (Combinatorial Chemistry)</i> 61:33-45 (1998)
	63.	Brody and Gold, "Aptamers as therapeutic and diagnostic agents," <i>Reviews in Molecular Biotechnology</i> 74:5-13 (2000)
	64.	Burger et al., "Experimental Corneal Neovascularization: Biomicroscopic, Angiographic, and Morphologic Correlation," <i>Cornea</i> 4:35-41 (1985/1986)
	65.	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," <i>Biochemistry</i> 35:14090-14097 (1996) (volume no. mistakenly listed as 6)
	66.	Burlina et al., "Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes," <i>Bioorganic & Medicinal Chemistry</i> 5:1999-2010 (1997)
↓	67.	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <i>Methods in Enzymology</i> 211:3-19 (1992)

EXAMINER

DATE CONSIDERED

12/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:

KC	68.	Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," <u>Nucleic Acids Research</u> 20:4581-4589 (1992)
	69.	Chowrira et al., "In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," <u>J. Biol. Chem.</u> 269:25856-25864 (1994)
	70.	Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <u>J. Am. Chem. Soc.</u> 113:6324-6326 (1991)
	71.	Connolly et al., "Binding and Endocytosis of Cluster Glycosides by Rabbit Hepatocytes," <u>The Journ. of Biol. Chem.</u> 257:939-945 (1982)
	72.	Conry et al., "Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration," <u>Clinical Cancer Research</u> 5:2330-2337 (1999)
	73.	Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," <u>Trends In Genetics</u> 12:510-515 (1996)
	74.	Detmar et al., "Overexpression of Vascular Permeability Factor/Vascular Endothelial Growth Factor and its Receptors in Psoriasis," <u>J. Exp. Med.</u> 180:1141-1146 (1994)
	75.	Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <u>Journal of Virology</u> 66:1432-1441 (1992)
	76.	Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <u>Nucleic Acids Research</u> 18:6353-6359 (1990) [sometimes referred to as Seela and Kaiser]
✓	77.	Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <u>Biopolymers</u> 48:39-55 (1998)

EXAMINER


DATE CONSIDERED

12/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.


FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-332-B (400/126)	Serial No. 10/652,791
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		McSwiggen et al.	
		Filing Date:	Group:
		August 29, 2003	

le	78.	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> 411:494-498 (2001)
	79.	Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila Melanogaster</i> Embryo Lysate," <i>The EMBO Journal</i> 20:6877-6888 (2001)
	80.	Elbashir et al., "RNA Interference is Mediated by 21- and 22-Nucleotide RNAs," <i>Genes and Development</i> 15:188-200 (2001)
	81.	Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <i>Delivery Strategies for Antisense Oligonucleotide Therapeutics</i> , edited by Akhtar, CRC Press, pp. 17-220 (1995)
	82.	Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," <i>Proc. Natl. Acad. Sci. USA</i> 87:6743-6747 (1990)
	83.	Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <i>Cell Transplantation</i> 8:47-58 (1999)
	84.	Fava et al., "Vascular Permeability Factor/Endothelial Growth Factor (VPF/VEGF): Accumulation and Expression in Human Synovial Fluids and Rheumatoid Synovial Tissue," <i>J. Exp. Med.</i> 180:341-346 (1994)
	85.	Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," <i>J. Am. Chem. Soc.</i> 113:4000-4002 (1991)
	86.	Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <i>Nature</i> 391:806-811(1998)
	87.	Fire, "RNA-triggered Gene Silencing," <i>IIIG</i> 15:358-363(1999)
	88.	Folkman et al., "Long-term Culture of Capillary Endothelial Cells," <i>Proc. Natl. Acad. Sci. USA</i> 76:5217-5221 (1979)
✓	89.	Folkman, Judah, "Tumor Angiogenesis," <i>Advances in Cancer Research</i> 43:175-203 (1985)

EXAMINER		DATE CONSIDERED	12/5/05
----------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003


Group:

KC	90.	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <u>Proc. Natl. Acad. Sci. USA</u> 83:9373-9377 (1986) [sometimes referred to as Frier]
	91.	Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <u>Nucleic Acids Research</u> 21:2867-2872 (1993)
	92.	Gold et al., "Diversity of Oligonucleotide Functions," <u>Annu. Rev. Biochem.</u> 64:763-797 (1995)
	93.	Gonzalez et al., "New Class of Polymers for the Delivery of Macromolecular Therapeutics," <u>Bioconjugate Chem.</u> , 10, 1068-1074 (1999)
	94.	Good et al., "Expression of small, therapeutic RNAs in human nuclei," <u>Gene Therapy</u> 4:45-54 (1997)
	95.	Grant et al., "Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor," <u>Diabetologia</u> 36:282-291 (1993)
	96.	Hall et al., "Establishment and Maintenance of a Heterochromatin Domain," <u>Science</u> 297:2232-2237 (2002)
	97.	Hammond et al., "An RNA-Directed Nuclease Mediates Post-Transcriptional Gene Silencing in <i>Drosophila</i> Cells," <u>Nature</u> 404:293-296 (2000)
	98.	Hermann and Patel, "Adaptive Recognition by Nucleic Acid Aptamers," <u>Science</u> 287:820-825 (2000)
	99.	Hofland and Huang, "Formulation and Delivery of Nucleic Acids," <u>Handbook of Exp. Pharmacol.</u> 137:165-192 (1999)
	100.	Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods," <u>VCH</u> , 331-417

EXAMINER 	DATE CONSIDERED 12/5/05
--	-------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:

101.	Hutvagner and Zamore, "A MicroRNA in a Multiple-Turnover RNAi Enzyme Complex," <u>Science</u> 297:2056-2060 (2002)
102.	Hutvagner et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the <i>let-7</i> Small Temporal RNA," <u>Science</u> 293:834-838 (2001)
103.	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," <u>Chem. Pharm. Bull.</u> 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
104.	Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," <u>Science</u> 229:345-352 (1985)
105.	Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," <u>Tetrahedron Letters</u> 34:301-304 (1993) (sometimes mistakenly referred to as Jsckke)
106.	Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," <u>Clinical Chemistry</u> 45:1628-1650 (1999).
107.	Jenuwein, "An RNA-Guided Pathway for the Epigenome," <u>Science</u> 297:2215-2218 (2002)
108.	Jolliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," <u>Fundam. Clin. Pharmacol.</u> 13:16-26 (1999)
109.	Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," <u>Tetrahedron Letters</u> 39:1131-1134 (1998)
110.	Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," <u>Antisense Research & Development</u> 2:3-15 (1992)
111.	Kaspereit-Rittinghausen et al., "Animal Model of Human Disease," <u>Am. J. Pathol.</u> , 139, 693-696 (1991)
112.	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)

EXAMINER

DATE CONSIDERED 12/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-332-B (400/126)	Serial No. 10/652,791
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		McSwiggen et al.	
		Filing Date:	Group:
		August 29, 2003	

KC	113. Koch et al., "Vascular Endothelial Growth Factor," <i>Journal of Immunology</i> 152:4149-4156 (1994)
/	114. Kusser, "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution," <i>Reviews in Molecular Biotechnology</i> 74:27-38 (2000)
/	115. Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," <i>Chemical Reviews</i> 95:2601-2627 (1995)
/	116. Lasic and Papahadjopoulos, "Liposomes Revisited," <i>Science</i> 267:1275-1276 (1995)
/	117. Lee and Larson, "Modified Liposome Formulations for Cytosolic Delivery of Macromolecules," <i>ACS Symposium Series</i> 752:184-192 (2000)
/	118. Lee and Lee, "Preparation of Cluster Glycosides of N-Acetylgalactosamine That Have Subnanomolar Binding Constants Towards the Mammalian Hepatic Gal/GalNAc-specific Receptor," <i>Glycoconjugates J.</i> 4:317-328 (1987)
/	119. Lee et al., "Expression of Small Interfering RNA's Targeted Against HIV-1 rev Transcripts in Human Cells," <i>Nature Biotechnology</i> 19:500-505 (2002)
/	120. Lepri et al., "Effect of Low Molecular Weight Heparan Sulphate on Angiogenesis in the Rat Cornea after Chemical Cauterization," <i>Journal of Ocular Pharmacology</i> 10:273-281 (1994)
/	121. L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α -Lactalbumin mRNA Levels in C1271 Mouse," <i>EMBO J.</i> 11:4411-4418 (1992)
/	122. Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," <i>Methods Enzymol.</i> 217:47-66 (1993)
/	123. Limbach et al., "Summary: the modified nucleosides of RNA," <i>Nucleic Acids Research</i> 22(12):2183-2196 (1994)
✓	124. Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," <i>J. Am. Chem. Soc.</i> 120:8531-8532 (1998)

EXAMINER		DATE CONSIDERED	12/5/05
----------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:

KC	125.	Lisiewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 90:8000-8004 (1993)
	126.	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <u>J. Biol. Chem.</u> 270(42):24864-24870 (1995)
	127.	Loakes, "The Applications of Universal DNA Base Analogues," <u>Nucleic Acids Research</u> 29:2437-2447 (2001)
	128.	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <u>Biochemistry</u> 32:1751-1758 (1993)
	129.	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <u>Nucleic Acids Research</u> 21:2585-2589 (1993)
	130.	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <u>Cell</u> 110:563-574 (2002)
	131.	Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs," <u>Molecular Membrane Biology</u> 16:129-140 (1999)
	132.	McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <u>Nucleosides & Nucleotides</u> 10:287-290 (1991)
	133.	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," <u>Proc. Natl. Acad. Sci. USA</u> 83:399-403 (1986)
	134.	McManus et al., "Gene Silencing Using Micro-RNA Designed Hairpins," <u>RNA</u> 8:842-850 (2002)
✓	135.	Mesmaeker et al., "Novel Backbone Replacements for Oligonucleotides," <u>American Chemical Society</u> , pp. 24-39 (1994)


EXAMINER

DATE CONSIDERED

12/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:

136.	Miyagishi and Taira, "U6 Promoter-driven siRNAs with Four Uridine 3' Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells," <u>Nature Biotechnology</u> 19:497-500 (2002)
137.	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," <u>Science</u> 256:992-996 (1992)
138.	Noonberg et al., <i>In vivo</i> generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," <u>Nucleic Acids Research</u> 22(14):2830-2836 (1994)
139.	Norrby, "Angiogenesis: new aspects relating to its initiation and control," <u>APMIA</u> 105:417-437 (1997)
140.	Novina et al., "siRNA-Directed Inhibition of HIV-1 Infection," <u>Nature Medicine</u> 1-6 (2002)
141.	Nykanen et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway," <u>Cell</u> 107:309-321 (2001)
142.	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," <u>Nucleic Acids Symp. Ser.</u> 27:15-16 (1992)
143.	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <u>Proc. Natl. Acad. Sci. USA</u> 89:10802-10806 (1992)
144.	Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <u>Biochimica et Biophysica Acta</u> 1238:86-90 (1995)
145.	Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <u>Biochemistry</u> 30:9914-9921 (1991)
146.	O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell</u> 79:315-328 (1994)

EXAMINER

DATE CONSIDERED

12/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:


147.	Ormerod et al., "Effects of Altering the Eicosanoid Precursor Pool on Neovascularization and Inflammation in the Alkali-burned Rabbit Cornea," <i>American Journal of Pathology</i> 137:1243-1252 (1990)
148.	Pandey et al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- α -Induced Angiogenesis," <i>Science</i> 268:567-569 (1995)
149.	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 92:5592-5596 (1995)
150.	Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> 6:1077-1087 (2000)
151.	Passaniti et al., "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Laboratory Investigation</i> 67:519-528 (1992)
152.	Paul et al., "Effective Expression of Small Interfering RNA in Human Cells," <i>Nature Biotechnology</i> 20:505-508 (2002)
153.	Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," <i>Nature</i> 344:565-567 (1990) (often mistakenly listed as Perrault)
154.	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <i>Science</i> 253:314-317 (1991)
155.	Pierce et al., "Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization," <i>Proc. Natl. Acad. Sci. USA</i> 92:905-909 (1995)
156.	Plate, "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas <i>in vivo</i> ," <i>Nature</i> 359:845-848 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:

KE	157.	Ponpipom et al., "Cell-Specific Ligands for Selective Drug Delivery to Tissues and Organs," <u>J. Med. Chem.</u> 24:1388-1395 (1981)
	158.	Reinhart and Bartel, "Small RNAs Correspond to Centromer Heterochromatic Repeats," <u>Science</u> 297:1831 (2002)
	159.	Reinhart et al., "MicroRNAs in Plants," <u>Genes & Development</u> 16:1616-1626 (2002)
	160.	Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <u>J. Am. Chem. Soc.</u> 113:5109-5111 (1991)
	161.	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <u>Science</u> 247:1222-1225 (1990)
	162.	Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <u>Proc. Natl. Acad. Sci. USA</u> 88:10591-10595 (1991)
	163.	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β -cyanoethyl protected ribonucleoside phosphoramidites," <u>Nucl Acids Res.</u> 18:5433-5441 (1990)
	164.	Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," <u>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</u> 23:941-949 (1999) [sometimes cited by RPI as <u>Prog Neuropsychopharmacol Biol Psychiatry</u> 23:941-949, 1999]
	165.	Schwarz et al., "Evidence that siRNAs Function as Guides, Not Primers, in the <i>Drosophila</i> and Human RNAi Pathways," <u>Molecular Cell</u> 10:537-548 (2002)
	166.	Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <u>Nucleic Acids Research</u> 15:3113-3129 (1987)
	167.	Senger et al., "Vascular permeability factor (VPF, VEGF) in tumor biology," <u>Cancer and Metastasis Reviews</u> 12:303-324 (1993)


EXAMINER

DATE CONSIDERED

6/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:

168.	Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <u>Nucleic Acids Research</u> 19:4247-4251 (1991)
169.	Shweiki et al., "Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis," <u>J. Clin. Invest.</u> 91:2235-2243 (1993)
170.	Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," <u>Science</u> 262:1566-1569 (1993)
171.	Sun, "Technology evaluation: SELEX, Giliad Sciences Inc.," <u>Current Opinion in Molecular Therapeutics</u> 2:100-105 (2000)
172.	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both <i>in vitro</i> in place of run-off and (G)-free transcriptions and <i>in vivo</i> as multi-sequences transcription vectors," <u>Nucleic Acids Research</u> 19:5125-5130 (1991)
173.	Takahashi et al., "Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis," <u>Cancer Research</u> 54:4233-4237 (1994)
174.	Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," <u>Nucleic Acids Research</u> 23:2259-2268 (1995)
175.	Turner et al., "Improved Parameters for Prediction of RNA Structure," <u>Cold Spring Harbor Symposia on Quantitative Biology Volume LII</u> , pp. 123-133 (1987)
176.	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <u>J. Am. Chem. Soc.</u> 109:3783-3785 (1987)
177.	Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <u>Genes & Development</u> 13:3191-3197 (1999)
178.	Tuschl, "RNA Interference and Small Interfering RNAs," <u>Chembiochem</u> 2:239-245 (2001)

EXAMINER

DATE CONSIDERED

12/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)



U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:


KC	179.	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <i>Proc. Natl. Acad. Sci. USA</i> 96:7053-7058 (1999)
	180.	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <i>FEBS Letters</i> 421:280-284 (1998)
	181.	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chemical Reviews</i> 90:544-584 (1990)
	182.	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <i>IIBS</i> 17:334-339 (1992)
	183.	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an <i>Escherichia coli</i> Formylmethionine tRNA," <i>J. Am. Chem. Soc.</i> 109:7845-7854 (1987)
	184.	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <i>Nucleic Acids Symposium Series</i> 31:163-164 (1994)
	185.	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," <i>Nucleic Acids Research</i> 21:3249-3255 (1993)
	186.	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," <i>Annu. Rev. Biochem.</i> 67:99-134 (1998)
	187.	Volpe et al., "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi," <i>Science</i> 297:1833-1837 (2002)
	188.	Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4 ⁺ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," <i>Journal of Virology</i> 65:5531-5534 (1994)

EXAMINER

DATE CONSIDERED

12/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

03-332-B
(400/126)

Serial No.

10/652,791

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

August 29, 2003

Group:

KC	189.	Wellstein and Czubayko, "Inhibition of Fibroblast Growth Factors," <u>Breast Cancer Research and Treatment</u> 38:109-119 (1996)
	190.	Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," <u>Nature Cell Biology</u> 2:70-75 (2000)
	191.	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," <u>Nucleic Acids Research</u> 23(14):2677-2684 (1995)
	192.	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," <u>Methods in Molecular Biology</u> 74:59-69 (1997)
	193.	Woo et al., "Taxol inhibits progression of congenital polycystic kidney disease," <u>Nature</u> , 368, 750-753 (1994)
	194.	Wu and Wu, "Receptor-mediated <i>in Vitro</i> Gene Transformation by a Soluble DNA Carrier System," <u>The Journ. of Biol. Chem.</u> 262:4429-4432 (1987)
	195.	Wu et al., "Cardiac defects and renal failure in mice with targeted mutations in <i>Pkd2</i> ," <u>Nat. Genet.</u> , 24, 75-78 (2000)
	196.	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," <u>Proc. Natl. Acad. Sci. USA</u> 90:6340-6344 (1993)
	197.	Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," <u>Cell</u> 101:25-33 (2000)
	198.	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," <u>Mol. Cell. Biol.</u> 10:4529-4537 (1990)
✓	199.	Ziche et al., "Angiogenesis Can Be Stimulated or Repressed <i>In Vivo</i> by a Change in GM3:GD3 Ganglioside Ratio," <u>Laboratory Investigation</u> 67:711-715 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-332-B (400/126)	Serial No. 10/652,791
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: August 29, 2003	Group: 1635



FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
KC	1.	90/14090	11/29/90	WO (Gillespie et al.)				
↓	2.	00/49035	08/24/00	WO (Sheen, Jen)				
↓	3.	01/06584	12/20/01	WO (Mushegian et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

KC	4.	International Search Report PCT/US03/05346 mailed October 17, 2003
	*	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> 411:494-498 (2001)

EXAMINER <i>U. BerfChay</i>	DATE CONSIDERED <i>12/1/05</i>
-----------------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. MBHB03-332-B (400/126)	Serial No. 10/652,791
2 ND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
(Use several sheets if necessary)		Filing Date: August 29, 2003	Group: 1635



FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
KC	*	WO 01/75164	10/11/01	WO (Tuschl et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).


	1.	International Search Report from PCT/US2004/011848 mailed November 16, 2004
KC	2.	Tuschl et al., "Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy", <i>Molecular Interventions</i> V. 2:158-165 (2002)
	3.	Caplen Natasha et al., "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems", <i>PNAS</i> V.98, 17:9742-9747 (2001)
	*	Miyagishi M. et al., "U6 Promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells", <i>Nature Biotechnology</i> , V.19, 5:497-500 (2002)
	4.	Brummelkamp et al., "A system for stable expression of short interfering RNAs in mammalian cells", <i>Science</i> V.296, 5567:550-553 (2002)

EXAMINER		DATE CONSIDERED	12/1/05
----------	--	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. MBHB03-332-B (400/126)	Serial No. 10/652,791
2ND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: August 29, 2003	Group: 1635

KC	5.	Leirdal M. et al., "Gene silencing in mammalian cells by preformed small RNA duplexes", Biochemical and Biophysical Research Communications, V.295: 744-748 (2002)
↓	*	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", Nature, V. 411, 6836: 494-498 (2001)
↓	6.	Bohula Erin et al., "The Efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript", Journal of Biological Chemistry, V. 278, 18:15991-15997 (2003)

EXAMINER 	DATE CONSIDERED 12/1/05
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.